Company Profile
Liquidia Corporation Stock Price, News & Analysis
Company overview
Business overview
Liquidia is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Liquidia is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Liquidia follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Liquidia sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
LQDA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Liquidia’s catalysts are still centered on YUTREPIA launch execution and any additional regulatory or commercial step around inhaled treprostinil. The market will care about whether the company can keep converting approval into durable adoption in pulmonary hypertension.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Source: Liquidia Corporation
- 02
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
Source: Liquidia Corporation
- 03
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
Source: Liquidia Corporation
- 04
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Source: Liquidia Corporation
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.